Trial Profile
CHINA RESOLUTE INTEGRITY STUDY Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use --A Prospective, Multi-center, Single Arm, Non-randomized Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jan 2016
Price :
$35
*
At a glance
- Drugs Zotarolimus (Primary)
- Indications Arteriosclerosis; Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis; Ischaemic heart disorders
- Focus Therapeutic Use
- Acronyms CHINA RESOLUTE INTEGRITY STUDY; CV-Resolute Integrity China
- Sponsors Medtronic
- 20 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 24 Jul 2015 New trial record